HK1256036A1 - 治療骨髓增生性障礙的方法 - Google Patents

治療骨髓增生性障礙的方法

Info

Publication number
HK1256036A1
HK1256036A1 HK18115088.1A HK18115088A HK1256036A1 HK 1256036 A1 HK1256036 A1 HK 1256036A1 HK 18115088 A HK18115088 A HK 18115088A HK 1256036 A1 HK1256036 A1 HK 1256036A1
Authority
HK
Hong Kong
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
HK18115088.1A
Other languages
English (en)
Inventor
伊麗莎白‧特雷胡布
理查德‧M‧杰克
Original Assignee
普羅麥迪奧股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 普羅麥迪奧股份有限公司 filed Critical 普羅麥迪奧股份有限公司
Publication of HK1256036A1 publication Critical patent/HK1256036A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
HK18115088.1A 2015-04-15 2018-11-26 治療骨髓增生性障礙的方法 HK1256036A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148005P 2015-04-15 2015-04-15
US201562218869P 2015-09-15 2015-09-15
PCT/US2016/027773 WO2016168612A1 (en) 2015-04-15 2016-04-15 Methods for treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
HK1256036A1 true HK1256036A1 (zh) 2019-09-13

Family

ID=57127338

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18110217.6A HK1250752A1 (zh) 2015-04-15 2018-08-09 治療骨髓增生性障礙的方法
HK18115088.1A HK1256036A1 (zh) 2015-04-15 2018-11-26 治療骨髓增生性障礙的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18110217.6A HK1250752A1 (zh) 2015-04-15 2018-08-09 治療骨髓增生性障礙的方法

Country Status (9)

Country Link
US (1) US20180318303A1 (zh)
EP (1) EP3283655A4 (zh)
JP (1) JP2018512164A (zh)
CN (1) CN108138234A (zh)
AU (1) AU2016248317A1 (zh)
CA (1) CA2983004A1 (zh)
HK (2) HK1250752A1 (zh)
RU (1) RU2017139122A (zh)
WO (1) WO2016168612A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2784234T3 (es) 2013-10-08 2020-09-23 Promedior Inc Métodos para el tratamiento de cánceres fibróticos
JP6852397B2 (ja) 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
NZ755835A (en) 2017-01-17 2023-12-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7248368B2 (ja) * 2017-03-01 2023-03-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高度に特異的な環状近接ライゲーションアッセイ
DE102017107661A1 (de) * 2017-04-10 2018-10-11 Universität Rostock SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort
BR112021001204A2 (pt) 2018-07-31 2021-04-27 Geron Corporation métodos de identificação de pacientes que provavelmente se beneficiarão do tratamento com um inibidor de telomerase
KR101962869B1 (ko) * 2018-08-02 2019-03-27 주식회사 우리메디칼 이미지 분석에 기반한 골수판독 지원 장치
JP2022522654A (ja) 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
EP3931207A1 (en) * 2019-03-01 2022-01-05 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
CN111426850B (zh) * 2020-01-15 2021-12-21 上海众启生物科技有限公司 用于阿尔茨海默症自身抗体检测的含dnajc8蛋白片段的组合物
EP3900789A1 (en) * 2020-04-23 2021-10-27 Universitätsklinikum Jena Pharmaceutical combination for the treatment of myeloproliferative neoplasms
CN113549597B (zh) * 2021-07-22 2022-03-25 浙江大学 一种人原发性骨髓纤维化细胞株及其应用
CN114752575B (zh) * 2022-04-07 2023-06-13 内蒙古工业大学 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
JP5822826B2 (ja) * 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
ES2784234T3 (es) * 2013-10-08 2020-09-23 Promedior Inc Métodos para el tratamiento de cánceres fibróticos

Also Published As

Publication number Publication date
WO2016168612A1 (en) 2016-10-20
RU2017139122A (ru) 2019-05-15
JP2018512164A (ja) 2018-05-17
AU2016248317A1 (en) 2017-11-09
CA2983004A1 (en) 2016-10-20
CN108138234A (zh) 2018-06-08
RU2017139122A3 (zh) 2019-08-28
EP3283655A4 (en) 2018-12-05
EP3283655A1 (en) 2018-02-21
US20180318303A1 (en) 2018-11-08
HK1250752A1 (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
HK1259336A1 (zh) 用於治療骨髓增生性病症的方法
HK1252741A1 (zh) 用於治療神經疾病的組合物和方法
HK1256036A1 (zh) 治療骨髓增生性障礙的方法
ZA201705673B (en) Methods for treating skin
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
EP3380121A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
IL247699A0 (en) Preparations and methods for the treatment of kidney disorders
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
EP3166610A4 (en) Methods for treating neurologic disorders
HK1252996A1 (zh) 用於治療癲癇的方法
HK1251965A1 (zh) 用於治療癲癇的方法
HK1245127A1 (zh) 治療腦疾病的方法和組合物
GB201502137D0 (en) Treatment
HK1248133A1 (zh) 治療神經母細胞瘤的方法
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
IL254336A0 (en) A new treatment method
HK1256371A1 (zh) 用於治療腫瘤的方法
GB201602011D0 (en) Treating skin disorders
GB201517995D0 (en) Products for treating psychogenic pain disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders